The markets recent declines have thrown up some great bargains for Foolish investors who arent afraid to invest against the grain.Three such bargains areHikma Pharmaceuticals (LSE: HIK),Shire (LSE: SHP) andAstraZeneca (LSE: AZN).
These three highly defensive pharma stocks are now trading at their lowest valuations in more than two years, presenting a rare opportunity for long-term investors.
Pipeline worries
2016 is going to be a tough year for Astra. The company is set to lose patent protection on its blockbuster Crestor blood thinner this year, and at the beginning of February management warned that as a result of patent expirations, Astras sales and earnings would fall by a low to mid-single-digit percentage in 2016. Many City analysts believe that Astras sales declines will be at the lower end of the range mentioned above.
Still, while Astras earnings are set to fall next year, management believes the company is still on trackto increase revenues by three-quarters to $45bn by 2023.Astras management is pinning its hopes on the groups best-in-class pipeline of opportunities, new drugs such asBrilinta, an anti-clotting drug,Durvalumab, andAZD9291. Whats more, to complement organic product development, Astra acquired several assets in a $10bn shopping spree last year to bolster its product pipeline and the group has had some success recently with the development of new oncology drugs.
All in all, Astras near-term outlook might be worrying, but as new treatments come to market, the group should return to growth. Investors will get paid to wait for the companys recovery as Astra currently supports a yield of 4.8%. The payout is covered one-and-a-half times by earnings per share, so it looks safe for now.
Deal concerns
Market jitters have pushed Shires shares to a 52-week low this week despite the fact that the company is now in a stronger position that it ever has been before. A string of deals has strengthened the companys treatment pipeline, and pre-tax profit is expected to grow by 11% this year. Earnings per share are set to increase by 12% for 2016 and after recent declines, the companys shares are trading at a forward P/E of only 16, a five-year low excluding one-off items.
Shires shares currently support a dividend yield of 0.4%, which isnt much, but the payout is covered more than 15 times by earnings per share, leaving plenty of room for payout growth.
Buyout jitters
Last year,Hikmaagreed to pay $2.65bn in cash and shares for peer Roxane. However yesterday, Hikma said Roxanes sales in 2015 were lower than the $680m it had estimated. As a result, Roxanes price tag has been reduced, from $1.18bn to $647m. Hikma is buying Roxane for its pipeline, not the companys products. In theory if everything goes to plan, over the long-term Hikma should benefit from the sudden reduction in price.
Hikmas earnings per share have expanded 130% since 2010 and City analysts have pencilled-in EPS growth of 16% for 2016. Based on this forecast the company is trading at a forward P/E of 23.2. Hikmas shares only offer a token dividend yield of 0.7%, although the payout is covered five times by earnings per share. If the company can repeat its performance of the last five years, a valuation of 23.2 times earnings for Hikmas shares seems appropriate.
And if you’re looking for other growth stocks like Hikma, our top analysts here at the Motley Fool have recently discovered a great opportunity. The company in question hasalready delivered a powerful return for investors over the years, and our analysts believe thecompany’s growth is only just getting started.
All is revealed in ourbrand new free report.
Click hereto check out the report – it’s completely free and comeswith nofurther obligation.
Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
